A61K 47/56
The modifying agent being an organic macromolecular compound
Official title: the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
A61K47/56 (The modifying agent being an organic macromolecular compound) appears on 6,973 US grants and 10,898 published applications in this corpus.
Search patents in A61K- Granted patents
- 6,973
- Published applications
- 10,898
- Assignees
- 3,416
- Inventors
- 16,691
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 8 | 0 |
| 1977 | 9 | 0 |
| 1978 | 6 | 0 |
| 1979 | 4 | 0 |
| 1980 | 15 | 0 |
| 1981 | 7 | 0 |
| 1982 | 8 | 0 |
| 1983 | 9 | 0 |
| 1984 | 4 | 0 |
| 1985 | 13 | 0 |
| 1986 | 13 | 0 |
| 1987 | 19 | 0 |
| 1988 | 22 | 0 |
| 1989 | 25 | 0 |
| 1990 | 28 | 0 |
| 1991 | 28 | 0 |
| 1992 | 44 | 0 |
| 1993 | 50 | 0 |
| 1994 | 45 | 0 |
| 1995 | 55 | 0 |
| 1996 | 62 | 0 |
| 1997 | 89 | 0 |
| 1998 | 101 | 0 |
| 1999 | 99 | 0 |
| 2000 | 63 | 0 |
| 2001 | 91 | 39 |
| 2002 | 94 | 133 |
| 2003 | 97 | 241 |
| 2004 | 71 | 224 |
| 2005 | 78 | 266 |
| 2006 | 110 | 264 |
| 2007 | 90 | 264 |
| 2008 | 103 | 316 |
| 2009 | 124 | 300 |
| 2010 | 177 | 425 |
| 2011 | 182 | 406 |
| 2012 | 219 | 407 |
| 2013 | 278 | 479 |
| 2014 | 343 | 540 |
| 2015 | 373 | 598 |
| 2016 | 369 | 621 |
| 2017 | 368 | 571 |
| 2018 | 407 | 563 |
| 2019 | 401 | 619 |
| 2020 | 371 | 536 |
| 2021 | 368 | 641 |
| 2022 | 332 | 579 |
| 2023 | 310 | 561 |
| 2024 | 297 | 536 |
| 2025 | 297 | 465 |
| 2026 | 197 | 304 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Therapeutic carbon nanomaterial H2S oxidants for biological polysulfide synthesis6 Oct 2026US 12,752,017 B2The Texas A&M University System
- Bio-functionalization of water-soluble poly(phenylene ehtylene)s6 Oct 2026US 12,753,271 B2Board of Regents, The University of Texas System
- Pharmaceutical composition for treatment or prevention of ischemic cardiovascular disease29 Sep 2026US 12,746,220 B2Industry-Academic Cooperation Foundation, Yonsei University
- Dynamic-covalent hydrogels with glucose-specific and glucose-responsive diboronate crosslinking29 Sep 2026US 12,746,277 B2University of Notre Dame du Lac
- Antitumor pharmaceutical composition and use thereof29 Sep 2026US 12,746,289 B2Jenkem Technology Co., Ltd. (Tianjin)
- Polymer-based therapeutics for inductive browning of fat8 Oct 2026US 2026/0306643 A1Purdue Research Foundation
- Human interleukin-2 variant or derivative thereof8 Oct 2026US 2026/0308220 A1Jiangsu Hengrui Medicine Co., Ltd.
- Targeted engineered interferon and uses thereof8 Oct 2026US 2026/0308221 A1Orionis Biosciences BV
- Glucagon-like peptide-1 receptor agonist variants and methods thereof1 Oct 2026US 2026/0295054 A1
- Glp-1r/gipr/gcgr triple agonist analogue and use thereof1 Oct 2026US 2026/0295055 A1Shenzhen Bay Laboratory
Most cited
By later US patents
- Non-immunogenic polypeptides2,007US 4,179,337 A1979
- Uncharged morpholino-based polymers having achiral intersubunit linkages1,700US 5,034,506 AAnti-Gene Development Group · 1991
- Polyhydroxyalkanoate compositions having controlled degradation rates1,516US 6,867,248 B1Metabolix, Inc. · 2005
- Alpha-morpholino ribonucleoside derivatives and polymers thereof900US 5,235,033 AAnti-Gene Development Group · 1993
- Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages851US 5,185,444 AAnti-Gene Deveopment Group · 1993